Tenofovir Disoproxil Maleate

CHEMBL6068332 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
635.5 g/mol
LogP
Phase
4

Tenofovir disoproxil maleate is the maleate salt form of tenofovir disoproxil, a prodrug NRTI used for HIV-1 and hepatitis B treatment. See tenofovir-disoproxil for complete pharmacological details. This alternative salt form has been studied as a pharmaceutical development option.

Masse moléculaire

635,5000 g/mol

TPSA

260,00 Ų

Mécanisme d'action

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C.O=C(O)/C=C\C(=O)O

InChI

InChI=1S/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1-/t14-;/m1./s1

Molecular Formula

C23H34N5O14P

HBD / HBA

3 / 18

Liaisons Rotatives

19

Atomes Lourds

43

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

Tenofovir disoproxil maleate is the maleate salt form of tenofovir disoproxil, a prodrug NRTI used for HIV-1 and hepatitis B treatment. See tenofovir-disoproxil for complete pharmacological details. This alternative salt form has been studied as a pharmaceutical development option.

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Yes, Tenofovir Disoproxil Maleate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL6068332. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 86280652. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.